Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.01), $0.12 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $811.1 million versus the consensus estimate of $773.8 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.13-3.17 billion, versus the consensus of $3.1 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.